Advertisement
Advertisement
VBI Vaccines Inc. (VBIV)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
As of 12:54PM EDT. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.9699 |
| Open | 0.9722 |
| Bid | 0.9690 x 900 |
| Ask | 0.9692 x 800 |
| Day's Range | 0.9550 - 1.0200 |
| 52 Week Range | 0.9500 - 4.3100 |
| Volume | |
| Avg. Volume | 2,090,222 |
| Market Cap | 249.174M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Zacks
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
